Haruno Masatora, Shimamura Ryuji, Ogawa Yoshiaki, Tanaka Hirofumi, Sakai Kenji, Araki Kenichi
Dept. of Internal Medicine, Chihaya Hospital.
Gan To Kagaku Ryoho. 2005 May;32(5):667-70.
The patient was a 73-year-old man. In March 2002, abdominal computed tomography revealed hepatocellular carcinoma (HCC) with tumor thrombi in the first branch of the portal vein (Vp3) and two hepatic vein trunks (Vv2). He had no hepatitis virus. Serum AFP and PIVKA-II levels were as high as 6,919 ng/ml and 91,700 mAU/ ml, respectively. He was treated by transcatheter hepatic arterial chemoembolization (TACE) 3 times. On post 1st TACE week 8, he received hepatic arterial infusion chemotherapy (low-dose cisplatin and 5-FU) for Vp3 Vv2 HCC. The patient is still alive with no recurrence after two years and six months since the initial TACE treatment.
该患者为一名73岁男性。2002年3月,腹部计算机断层扫描显示肝细胞癌(HCC),门静脉第一分支(Vp3)和两条肝静脉主干(Vv2)有瘤栓。他没有感染肝炎病毒。血清甲胎蛋白(AFP)和异常凝血酶原(PIVKA-II)水平分别高达6919 ng/ml和91700 mAU/ml。他接受了3次经导管肝动脉化疗栓塞术(TACE)。在第一次TACE术后第8周,他接受了针对Vp3 Vv2 HCC的肝动脉灌注化疗(低剂量顺铂和5-氟尿嘧啶)。自首次TACE治疗以来,两年零六个月后,该患者仍然存活且未复发。